Business · 09/04/2014

FDA Releases Draft Guidance for Meetings with OOPD

The Food and Drug Administration (FDA) has released a draft guidance document to help industry, researchers, patient groups, and FDA staff prepare for meetings with the Office of Orphan Products Development (OOPD) regarding orphan drug designations, humanitarian device designations, rare pediatric disease designations, and other orphan product-related topics.